Epimedium Prenylflavonoid (EP) Extract for Osteoporosis and Cardiovascular Disease

Summary

The primary objective of the trial is to develop Epimedium Prenylflavonoid (EP) extract as a pharmaceutical-quality intervention for post-menopausal osteoporosis and cardiovascular disease. There will be 3 cohorts of 10 healthy men each for the Phase 1 study. In each cohort, 8 men will receive the Epimedium capsules and 2 men will received the matched controls.

Timeline

Start

2016-10

Primary completion

2017-01

Completion

2017-10

Drugs

Indications